ArticleJACC. Case reports2026
Recurrent Pulmonary Embolism After Pulmonary Endarterectomy During Rivaroxaban Therapy in a Resource-Limited Setting.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- When Resources Define Operability After Pulmonary Endarterectomy.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecurrent pulmonary embolism after endarterectomy despite adequate anticoagulation in high-risk patients remains a significant clinical challenge in low and middle-income countries. CASE SUMMARY: We report the case of 37-year-old man with hyperhomocysteinemia and prior pulmonary endarterectomy who presented with recurrent pulmonary embolism while on rivaroxaban. Imaging demonstrated a large thrombus in the right pulmonary artery with right ventricular dysfunction on echocardiography. In the absence of right heart catheterization, pulmonary hypertension could not be established; therefore, the case was managed as recurrent pulmonary embolism. Given high surgical risk and lack of advanced cardiopulmonary support, the patient was treated with systemic thrombolysis, inferior vena cava filter placement, anticoagulation escalation, and initiation of riociguat. DISCUSSION: This case highlights the challenges of managing recurrent pulmonary embolism in low-resource settings and underscores the importance of individualized therapeutic strategies. TAKE-HOME MESSAGE: Careful risk stratification and switching of anticoagulation should be considered for patients with recurrent pulmonary embolism and hyperhomocysteinemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.